– Plans for filing an IND was agreed with the FDA in a recent meeting –
Author: Ken Dropiewski
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy.
AIRS Medical Partners with Starvision to Bring SwiftMR® MRI Technology to Radiology Practices Throughout Germany
SEOUL, South Korea, Jan. 21, 2025 /PRNewswire/ — AIRS Medical has finalized a landmark agreement with Starvision, a leading radiological practice network in Germany, to bring its advanced MRI reconstruction technology, SwiftMR, to diagnostic imaging practices in Hannover and Munich. This…
SIRPAD – WORLD’S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT
TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ — Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with over 1,250 patients now enrolled. The…
Advanced Bifurcation Systems Inc. Secures $20.8 Million in Financing and Expands Board of Directors
LIVERMORE, Calif., Jan. 17, 2025 /PRNewswire/ — Advanced Bifurcation Systems Inc. (ABS), a leader in innovative solutions for bifurcation lesions in coronary angioplasty, announces the successful closure of a $20.8 million Simple Agreement for Future Equity (SAFE) financing round. The…
Investor Insights: Mike Carusi Lightstone Ventures – What do you look for when investing?
Medtronic drives continued momentum with new data and case presentations for Affera™ Mapping and Ablation System and PulseSelect™ at AF Symposium
JANUARY 17, 2025 – Medtronic, a global leader in healthcare technology, today announced new data and case presentations for the company’s pulsed field ablation (PFA) technologies, Affera™ Mapping and Ablation System with Sphere-9™ Catheter and PulseSelect™, to be presented at the […]
SandboxAQ Announces Collaboration with Mayo Clinic to Advance Cardiovascular Disease Monitoring in Amyloidosis
Expanded relationship includes joint research studies to test the feasibility of a combined electrocardiogram and magnetocardiogram approach using SandboxAQ’s Quantitative AI to integrate and interpret the results PALO ALTO, Calif., Jan. 17, 2025 /PRNewswire/ — SandboxAQ, a leader in…
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and…
MedRhythms’ InTandem® Rehabilitation System for Chronic Stroke Gait Impairment Receives Final Medicare Payment Determination from CMS
The pricing determination for HCPCS code E3200 will take effect on April 1, 2025 PORTLAND, Maine, Jan. 16, 2025 /PRNewswire/ — MedRhythms, Inc. today announced that InTandem®, the company’s flagship rehabilitation system for chronic stroke gait impairment, received a final pricing…
